Bone fibrosarcoma

Summary

Bone fibrosarcoma (MONDO:0002619) is a disease. A subtype of fibrosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bone fibrosarcoma
Mondo ID	MONDO:0002619
DOID	DOID:3354
NCIT	C6604
UMLS	C2733623
MedGen	404782
GARD	0023191
Anatomy (UBERON)	UBERON:0002481
Is cancer (heuristic)	no

Also known as: bone fibrosarcoma · bone tissue fibrosarcoma (disease) · fibrosarcoma of bone · fibrosarcoma of the bone

Data availability: 1 cell line.

Disease family

This is a subtype of fibrosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesenchymal cell neoplasm › fibroblastic neoplasm › fibrosarcoma › bone fibrosarcoma

Related subtypes (10): conventional fibrosarcoma, pediatric fibrosarcoma, kidney fibrosarcoma, breast fibrosarcoma, heart fibrosarcoma, central nervous system fibrosarcoma, small intestinal fibrosarcoma, liver fibrosarcoma, low grade fibromyxoid sarcoma, dermatofibrosarcoma protuberans

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.